The absence of ADCC by nivolumab in vitro.

Slides:



Advertisements
Similar presentations
Fig. 1. Specific cell lysis of targets preincubated with core 131 or IRIV‐core 131. (A) JY or T2 cells were pulsed with 1 or 10 µg/ml of soluble (black.
Advertisements

Melanoma donor (MD) NK cells are functionally impaired/exhausted.
by JoAnn Castelli, Elaine K
CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production by Giuseppe Sconocchia, Laura Campagnano, Domenico Adorno, Angela.
Impaired negative regulation of homeostatically proliferating T cells
by Norman Nausch, Ioanna E
Uptake of T-MPs for DC maturation and antigen presentation.
by Éric Aubin, Réal Lemieux, and Renée Bazin
Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach  Jeremiah.
H31m1-PDL1 cells form progressively growing tumors in WT mice.
IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.
Cetuximab treatment increases IFNγ receptor 1 expression.
Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J
KIR2DS2 recognizes the HCV peptide LNP.
Rapamycin inhibits TCR/CD3 engagement-dependent HIF-1α protein expression. Rapamycin inhibits TCR/CD3 engagement-dependent HIF-1α protein expression. Human.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Oktay Kirak, MD, Gert Riethmüller, MD 
IRF4 expression is modulated by the signaling of IL-2 family cytokines
PD-1 blockade enhances T-cell function.
IRF4 expression regulates the sensitivity of CD8+ T cells to IL-2, IL-15, and IL-7. IRF4 expression regulates the sensitivity of CD8+ T cells to IL-2,
Exosome-mediated inhibition of T cells is reversible.
Volume 21, Issue 4, Pages (April 2013)
M-MDSC:mast cell cross-talk in the regulation of TNFα production.
Change in antibody-dependent cellular cytotoxicity between baseline and day 15, day 30, and day 45 for cohort 1 and 2 versus cohort 3. Change in antibody-dependent.
KIR-CARs/Dap12 trigger robust antigen-specific cytotoxicity in vitro.
Effect of the PD-1–B7-H1 interaction on cell proliferation potential and drug sensitivity in MOSTI-1 cells. Effect of the PD-1–B7-H1 interaction on cell.
Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.
Possible mechanisms of recognition of MHCIlow tumor cells by NSCs
In vitro invasion assays were done in the Chemicon invasion chamber containing extracellular matrix. In vitro invasion assays were done in the Chemicon.
Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+
Flow cytometric analysis of T cell activation.
Cytotoxicity of p5399–107-induced CTL cells.
Anti-CD20 CAR mRNA enhances exPBNK in vitro cytolytic activity against CD20+ B-NHL cells and rituximab-resistant cells. exPBNK were electroporated in the.
Kinetic of NFAT-CBR expression.
Consequences of ICAM-1 expression modulation on the lysis of T1 and G1 cells. Consequences of ICAM-1 expression modulation on the lysis of T1 and G1 cells.
CLL-1 expression in patients with AML and normal donors.
PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.
IL-13Rα2 promotes cell survival and proliferation.
PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.
ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.
IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion. IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion.
Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.
Canonical but not adaptive NK-cell function is suppressed by Tregs.
Effect of nivolumab or ipilimumab on immune responses to vaccination in cynomolgus monkeys. Effect of nivolumab or ipilimumab on immune responses to vaccination.
Activation of Vγ9 T cells by three distinct stimuli is CD277 dependent
Expression of B7-H1, B7-DC, and PD-1 on B cells.
CD19-CAR-T cells with short and long spacers show specific in vitro function. CD19-CAR-T cells with short and long spacers show specific in vitro function.
Limited PD-1 expression in normal human tissues.
PD-1 expression in ovarian cancer.
Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.
PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.
Characterizing an A*1101-restricted SSC-specific CD8+ cytotoxic T-cell clone. Characterizing an A*1101-restricted SSC-specific CD8+ cytotoxic T-cell clone.
Trametinib and combination promote moDC maturation and decrease moDC viability. Trametinib and combination promote moDC maturation and decrease moDC viability.
Effect of bevacizumab on the proliferation of A2780 cells.
CpG oligodeoxynucleotide (CpG ODN)–induced activation of different types of primary malignant B cells. CpG oligodeoxynucleotide (CpG ODN)–induced activation.
αvβ6 functional assays in the β cell line using blocking antibodies.
Target-dependent T cell–mediated cytotoxicity of HER2-TDB.
LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.
In the presence of human monocytes, estradiol increased breast cancer cell dissemination to the periphery via CCL2 and CCL5. In the presence of human monocytes,
Expression of chemokine receptors in A-498 cell line.
Effect of BCAA on the progression of cell cycle, expression of p21CIP1, and induction of apoptosis in HepG2 cells in the presence and absence of visfatin.
In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.
Frequency of CD4+CD25+FoxP3+ and CD4+CD25+CD127low T cells in unactivated PBMCs from healthy donors. Frequency of CD4+CD25+FoxP3+ and CD4+CD25+CD127low.
Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced proliferation in HepG2 cells. Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced.
RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.
DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.
TRP1 transnuclear CD8 T cells are tumoricidal in vitro.
Expression of CAR, endogenous TCR, and target-cell receptors.
Presentation transcript:

The absence of ADCC by nivolumab in vitro. The absence of ADCC by nivolumab in vitro. IL-2–activated human PBMCs (effector cells) were incubated with activated human CD4+ T cells (target cells) in an effector-to-target cell ratio of 50:1 in the presence of serial dilutions of nivolumab or a positive control anti-MHC class I antibody for 3 hour at 37°C. A–C, data from three individual ADCC assays using cells from different donors are shown. Purified CD4+ T cells were activated by coated anti-CD3 antibody (4 μg/mL) plus soluble anti-CD28 antibody (1 μg/mL) and IL-2 (100 U/mL) for 3 days. PD-1 expression on activated CD4+ T cells in each of the ADCC assays is shown in the right (solid line for PD-1, gray line for isotype control). Changyu Wang et al. Cancer Immunol Res 2014;2:846-856 ©2014 by American Association for Cancer Research